Health

XChange TEC.INC RECEIVES NASDAQ MINIMUM BID PRICE DEFICIENCY NOTICE

SHANGHAI, Nov. 12, 2024 /PRNewswire/ -- XChange TEC.INC (NASDAQ: XHG) (the "Company"), today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") datedNovember 8, 2024 stating that the Company is not in compliance with the requirement to maintain a mi...

2024-11-13 07:00 708

Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI

Highlights: * ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patients * Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint, as measured by change in forced vital capacity (FVC) at 12 weeks CAMBRIDGE, Mass., Nov. 12, 2024 /...

2024-11-12 22:00 669

Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing

* Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. * Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug P...

2024-11-12 21:15 1077

2024 Tsingke High-Impact Literature Compilation - Gene Synthesis

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke  has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number of high-level academic papers published using Tsingke's products and services has grown steadily year after year, ...

2024-11-12 18:09 758

Tsingke Successfully Showcases Innovations at BIO-Europe 2024

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke proudly concluded its participation in BIO-Europe 2024, held fromNovember 4 to 6 inStockholm, Sweden. As one of the premier global events for the biotechnology, pharmaceutical, and investment sectors, over 5,500 attendees ...

2024-11-12 17:07 722

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Glo...

2024-11-12 08:00 921

HoneyNaps AI Diagnostic Medical Software as Featured in International Journal "Digital Health"

- Published clinical study on sleep apnea patients in the prestigious journal Digital Health - Clinical research on HoneyNaps SOMNUM validates its clinical efficacy BOSTON, Nov. 11, 2024 /PRNewswire/ -- Medical AI company HoneyNaps has published a paper demonstrating the clinical value and effic...

2024-11-11 22:00 724

Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.

Acquisition Strengthens Lakeside's Pharmaceutical Logistics Capabilities in China, Projected to Add US$7 Million in Annual Revenue ITASCA, Ill., Nov. 11, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain s...

2024-11-11 21:45 1270

DermRays Revolutionizing At-Home Laser Hair Removal with Innovative New Products

PLEASANTON, Calif., Nov. 11, 2024 /PRNewswire/ -- As anticipation grows around  DermRays' latest developments, industry insiders are abuzz with speculation about the future direction of the company's product line. Whether through a potential upgrade to theV8S Pro

2024-11-11 21:00 645

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...

2024-11-11 20:30 821

Professor Narayanan Parameswaran's team at Michigan State University announced that Red Ginseng is effective for intestinal health and preventing bone loss

JEJU, South Korea, Nov. 11, 2024 /PRNewswire/ -- Professor Narayanan Parameswaran's team at the Department of Physiology atMichigan State University announced the results of a study that showed that consuming red ginseng is effective for bone and intestinal health through intestinal microbiota ba...

2024-11-11 13:17 1048

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...

2024-11-11 08:07 1093

Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO)& 4th International Congress of the Asian Oncology Society (AOS2024)

XI'AN, China, Nov. 9, 2024 /PRNewswire/ -- On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International  Congress of the Asian Oncology Society (AOS2024) . This esteemed ...

2024-11-09 14:45 3365

Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024

Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...

2024-11-08 22:00 2492

Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference

SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...

2024-11-08 22:00 2272

Samsung Biologics earns ISO certifications in recognition of business excellence

* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...

2024-11-08 20:00 1208

Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...

2024-11-08 18:01 1088

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...

2024-11-08 17:45 1028

Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial

* Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers * Infinitopes' proprietary vector delivery sys...

2024-11-08 16:30 1410

WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards

SHANGHAI and SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is ...

2024-11-08 11:27 1591
12345 ... 279